BSIM Therapeutics announces selection of candidate compound for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
15 November, 2021
BSIM Therapeutics is pleased to announce the selection of its first drug candidate, BSIM-3A05D, a compound designed to address hereditary and wild-type transthyretin amyloidosis with cardiomyopathy presentation (ATTR-CM). ATTR-CM is a progressive and potentially fatal disease characterized by deposition of transthyretin (TTR) amyloid in the heart’s myocardium, and leading to heart failure. BSIM-3A05D unmatched binding affinity to transthyretin and its optimal pharmacokinetic properties holds high potential for a safe and efficacious treatment of ATTR-CM, and opens up new possibilities for the treatment of a growing population diagnosed with TTR-mediated cardiac amyloidosis, both as monotherapy or in combination therapies.
For full information, download the Press Release below.